High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients
- PMID: 20168200
- DOI: 10.1097/QAD.0b013e328337b161
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients
Abstract
Objectives: To evaluate the prevalence of 25-hydroxyvitamin D [25(OH)D] deficiency in HIV-positive patients, a population at risk for osteoporosis.
Design: Retrospective assessment of vitamin D levels by season and initiation of combined antiretroviral therapy (cART).
Methods: 25(OH)D was measured in 211 HIV-positive patients: samples were taken before initiation of cART from February to April or from August to October as well as 12 (same season) and 18 months (alternate season) after starting cART. 1,25-Dihydroxyvitamin D [1,25(OH)2D] was measured in a subset of 74 patients. Multivariable analyses included season, sex, age, ethnicity, BMI, intravenous drug use (IDU), renal function, time since HIV diagnosis, previous AIDS, CD4 cell count and cART, in particular nonnucleoside reverse transcriptase inhibitor (NNRTI) and tenofovir (TDF) use.
Results: At baseline, median 25(OH)D levels were 37 (interquartile range 20-49) nmol/l in spring and 57 (39-74) nmol/l in the fall; 25(OH)D deficiency less than 30 nmol/l was more prevalent in spring (42%) than in fall (14%), but remained unchanged regardless of cART exposure. In multivariable analysis, 25(OH)D levels were higher in white patients and those with a longer time since HIV diagnosis and lower in springtime measurements and in those with active IDU and NNRTI use. 1-Hydroxylation rates were significantly higher in patients with low 25(OH)D. Hepatitis C seropositivity, previous AIDS and higher CD4 cell counts correlated with lower 1,25(OH)2D levels, whereas BMI and TDF use were associated with higher levels. In TDF-treated patients, higher 1,25(OH)2D correlated with increases in serum alkaline phosphatase.
Conclusion: Based on the high rate of vitamin D deficiency in HIV-positive patients, systematic screening with consideration of seasonality is warranted. The impact of NNRTIs on 25(OH)D and TDF on 1,25(OH)2D needs further attention.
Comment in
-
Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use?AIDS. 2011 Mar 27;25(6):873-4. doi: 10.1097/QAD.0b013e32834542fa. AIDS. 2011. PMID: 21412064 No abstract available.
Similar articles
-
Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population.Clin Infect Dis. 2011 Feb 1;52(3):396-405. doi: 10.1093/cid/ciq158. Clin Infect Dis. 2011. PMID: 21217186
-
Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic.Eur Rev Med Pharmacol Sci. 2013 May;17(9):1218-32. Eur Rev Med Pharmacol Sci. 2013. PMID: 23690192 Review.
-
Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.HIV Med. 2005 May;6(3):145-50. doi: 10.1111/j.1468-1293.2005.00278.x. HIV Med. 2005. PMID: 15876279
-
Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.AIDS. 2010 Jul 31;24(12):1923-8. doi: 10.1097/QAD.0b013e32833c3281. AIDS. 2010. PMID: 20588161
-
Vitamin D and calcium abnormalities in the HIV-infected population.Endocrinol Metab Clin North Am. 2014 Sep;43(3):743-67. doi: 10.1016/j.ecl.2014.05.005. Epub 2014 Jun 30. Endocrinol Metab Clin North Am. 2014. PMID: 25169565 Review.
Cited by
-
Vitamin D-related host genetic variants alter HIV disease progression in children.Pediatr Infect Dis J. 2013 Nov;32(11):1230-6. doi: 10.1097/INF.0b013e31829e4d06. Pediatr Infect Dis J. 2013. PMID: 23736144 Free PMC article.
-
Physiologic frailty and fragility fracture in HIV-infected male veterans.Clin Infect Dis. 2013 May;56(10):1498-504. doi: 10.1093/cid/cit056. Epub 2013 Feb 1. Clin Infect Dis. 2013. PMID: 23378285 Free PMC article.
-
Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.Osteoporos Int. 2016 May;27(5):1737-45. doi: 10.1007/s00198-015-3432-3. Epub 2015 Dec 11. Osteoporos Int. 2016. PMID: 26659069 Clinical Trial.
-
Vitamin D levels and their impact on mineral metabolism in HIV infected patients: an exploratory study.Clin Cases Miner Bone Metab. 2017 Jan-Apr;14(1):18-22. doi: 10.11138/ccmbm/2017.14.1.018. Epub 2017 May 30. Clin Cases Miner Bone Metab. 2017. PMID: 28740520 Free PMC article.
-
Vitamin D Status Modulates Inflammatory Response in HIV+ Subjects: Evidence for Involvement of Autophagy and TG2 Expression in PBMC.Int J Mol Sci. 2020 Oct 13;21(20):7558. doi: 10.3390/ijms21207558. Int J Mol Sci. 2020. PMID: 33066266 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous